• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Patients with Diabetes Not at Highest Risk for Contrast-Induced Nephrotoxicity

Article

New study challenges common belief and finds patients with a history of renal disease, hypertension or heart disease were more likely to suffer renal insufficiency.

Patients with diabetes are not the highest risk group for developing contrast-induced nephrotoxicity as commonly believed, say researchers from Northwestern Memorial Hospital-Northwestern University in Chicago.

Instead, patients with a history of renal disease, hypertension or heart disease were more likely to suffer renal insufficiency, putting them at greater risk, according to their study, designed to find which group of patients at highest risk for contrast-induced nephrotoxicity. The results were presented at the American Roentgen Ray Society Annual Meeting this week in Vancouver, Canada.

Researchers evaluated 2,404 patients who underwent an estimated glomerular filtration rate (eGFR) test immediately before undergoing a CT examination. This allowed the researchers to see if the traditional risk factors accurately predicted reduced renal function.

“Patients with history of renal disease, hypertension, and heart disease had significantly higher odds of having abnormal eGFR,” said Vahid Yaghmai, MD, one of the study’s authors. This was not found in patients with a history of diabetes.

Yaghmai suggested eGFR be performed on the patients who indicate, via survey, that they are at high risk of such nephrotoxicity. “Measuring eGFR right before the CT scan can help us more accurately determine at-risk patients,” he said.

Recent Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Can 18F-Floutufolastat Bolster Detection of PCa Recurrence in Patients with Low PSA Levels After Radical Prostatectomy?
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
© 2024 MJH Life Sciences

All rights reserved.